Which of the following drugs does not act by blocking Gp IIb/IIIa receptors?
**Core Concept**
The Gp IIb/IIIa receptors are integral to platelet aggregation, playing a key role in platelet-platelet interactions and thrombus formation. These receptors are activated by fibrinogen binding, leading to platelet aggregation through cross-linking. Drugs targeting Gp IIb/IIIa receptors aim to inhibit platelet aggregation, primarily used in acute coronary syndromes.
**Why the Correct Answer is Right**
Fibrinolytic agents, such as alteplase, tenecteplase, and reteplase, work by activating plasminogen to plasmin, which then breaks down fibrin clots, rather than inhibiting platelet aggregation. This class of drugs does not act by blocking Gp IIb/IIIa receptors but instead targets the fibrinolytic pathway. The mechanism of action of fibrinolytic agents involves the conversion of plasminogen to plasmin by tissue plasminogen activator (tPA).
**Why Each Wrong Option is Incorrect**
**Option A:** Abciximab, a monoclonal antibody, binds to the Gp IIb/IIIa receptor, preventing fibrinogen binding and subsequent platelet aggregation. This action is consistent with the mechanism of Gp IIb/IIIa receptor blockade.
**Option B:** Eptifibatide is a synthetic peptide that inhibits the Gp IIb/IIIa receptor by binding to the receptor's ligand-binding site, preventing fibrinogen binding and platelet aggregation. This action is consistent with the mechanism of Gp IIb/IIIa receptor blockade.
**Option C:** Tirofiban is a non-peptide antagonist of the Gp IIb/IIIa receptor, which binds to the receptor's ligand-binding site, preventing fibrinogen binding and platelet aggregation. This action is consistent with the mechanism of Gp IIb/IIIa receptor blockade.
**Clinical Pearl / High-Yield Fact**
When considering antithrombotic therapy, it's essential to differentiate between drugs that inhibit platelet aggregation (e.g., Gp IIb/IIIa receptor blockers) and those that dissolve clots (e.g., fibrinolytic agents). This distinction is crucial for managing acute coronary syndromes and preventing bleeding complications.
**Correct Answer:** D. Fibrinolytic agents, such as alteplase, tenecteplase, and reteplase, work by activating plasminogen to plasmin, which then breaks down fibrin clots, rather than inhibiting platelet aggregation.